Health Boards
This review by Spherix Global Insights a business intelligence and market research company suggests that more and more US rheumatologists are prescribing Cosentyx for psoriatic arthritis
Source: spherixglobalinsights.com
Quote:
US rheumatologists are increasingly adopting Novartis’ IL-17 inhibitor, Cosentyx, into their treatment algorithm for psoriatic arthritis (PsA). Cosentyx users report high levels of satisfaction and excitement about the results their PsA patients are achieving with the latest biologic, with over one-quarter of current users citing that they are extremely satisfied with the agent. Furthermore, half of current non-users anticipate initiating trial of Cosentyx within the next three months.
With Cosentyx prescriptions in PsA on the rise, over one-third of rheumatologists believe that Janssen’s Stelara is the most likely to be replaced. Additionally, one-third of rheumatologists also report that Cosentyx has a significant efficacy advantage over Stelara.
With respect to Celgene’s Otezla, rheumatologists believe Cosentyx has a significant advantage over Otezla regarding efficacy in PsA. Indeed, rheumatologists report lower overall satisfaction with the PDE4 inhibitor than with the biologics available in PsA.
Cosentyx appears to be paving the PsA highway for IL-17 inhibitors, much like it paved the way for early adoption of Eli Lilly’s Taltz (ixekizumab) in Psoriasis. Indeed, the vast majority of surveyed rheumatologists foresee a role for Taltz, as well as for Valeant and AstraZeneca’s Siliq (brodalumab) in the future treatment of PsA. Furthermore, the majority of rheumatologists agree that the addition of IL-17 inhibitors as treatment options will greatly improve their ability to efficiently treat PsA.
Source: spherixglobalinsights.com